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Background: The Inﬂuenza A virus has constant variations, giv-
ng rise to the emergence of new strains. In each infection the
uman body produces antibodies, but when a new inﬂuenza virus
merges the preformed antibodies do not recognize it. But also
fter exposure induce antibody production and a memory immune
esponse. In April 2009 there was a rise in ﬂu cases in Mexico City,
hat later turned into a pandemic. Objective: To evaluate the pres-
nce of antibodies against the seasonal inﬂuenza virus (IAVS) and
he new virus (IAVN) during the 2009 pandemic.
Methods: We studied ﬁve work centers (3 hospitals and 2 uni-
ersities) with a total of 1595 blood samples from people without
nﬂuenza virus infection and with different risk (exposure and vac-
ination), age and sex. Antibody detection was performed by the
echnique of hemagglutination inhibition. As viral antigen, IAVN
nd IAVS were used.
Results: 25.5% presented antibodies IAVS and 41% against IAVN.
f all the people included, 24% had received IVAS vaccine and of
hese, 52% had antibody titers against both viruses, only 8% against
he IAVS, and 44% against IAVN. The average age of participants
as 35 years. The greatest number of people with antibodies and
igher titers corresponded to hospital staffs. The antibody titerwas
reater for IAVN than IAVS, even if they had received the vaccine
AVS.
Conclusion: The greatest number of people with antibodies
o both viruses was the hospital staff and was signiﬁcant in the
ase of new virus (p <0.002), indicating that their exposure was
reater when dealing with infected patients. It is interesting to
ote that hospital staff is vaccinated annually against IAVS, how-
ver the number of people with antibodies to the seasonal virus
as low. The presence of antibodiesmayprovide guidance on some
spects such as proximity or exposure to the virus or the habilitynfectious Diseases 16S (2012) e2–e157
to respond immunologically to viral stimulation, virus circulation,
and the possibility of partial or weak protection of a vaccine.
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126832 “Multicenter Study for Detection of antibodies against the
new virus inﬂuenza A (H1N1)” supported by CONACYT.
http://dx.doi.org/10.1016/j.ijid.2012.05.222
Type: Poster Presentation
Final Abstract Number: 40.061
Session: Virology and Viral Infections (Non-HIV)
Date: Thursday, June 14, 2012
Time: 12:45-14:15
Room: Poster & Exhibition Area
Hepatitis B and hepatitis C viruses’ infections among anti-
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Background:AlthoughARVhas signiﬁcantly reducedHIV/AIDS-
related deaths, co-infection with HBV and HCV viruses have
increasingly contributed to the morbidity and mortality associated
with HIV infection. The aim of this study was to investigate exist-
ing trend and future threats of HBV and HCV co-infections with
HIV, and explore the relation of HBV markers among ARV-naïve
and experienced subjects co-infected with HIV.
Methods: A total of 500 frozen HIV positive plasma and
serum samples collected from ARV-naïve (n=250) and experienced
(n=250) subjects seeking VCT and ARV services in Bethezata Health
Services P.L.C and Bethel Teaching General Hospital in Ethiopia
were screened for HBsAg, anti-HBs, HBeAg, and anti-HCV using a
rapid two-site sandwich immuno-chromatographic assay. Samples
screened positive for HBsAgwere conﬁrmed using third generation
ELISA.
Results:Of the500 specimens tested, 15(3%), 58(11.6%), 3(0.6%),
and 18(3.6%) were positive for HBsAg, anti-HBs, HBeAg, and
anti-HCV markers respectively. Three (0.6%) patients were tested
positive for both HBsAg and HBeAg, whereas 1(0.2%) was tested
positive for HBsAg and anti-HBs. No patient was identiﬁed positive
for both HBeAg and anti-HBs. Of 250 ARV naïve subjects tested, 8
(3.2%), 33 (13.2%), 2 (0.8%), 10 (4%), 2(0.8%), and 1(0.2%) were posi-
tive for HBsAg, anti-HBs, HBeAg, anti-HCV, HBsAg and HBeAg, and
HBsAg and anti-HBs respectively. Of 250 ARV-experienced subjects
tested, 7 (1.4%), 25 (5%), 1 (0.2%), 8 (3.2%), 0(0%), and 1(0.2%) were
positive for HBsAg, Anti-HBs, HBeAg, anti-HCV, HBsAg and HBeAg,
and HBsAg and anti-HBs respectively.
Conclusion: HBV and HCV infections were not signiﬁcantly dif-
ferent between persons who were or who were not on ART, which
suggests that the twogroupshave equal chances to be infectedwith
these two infections, despite diseaseprogression. CurrentHIV/AIDS
treatment algorithm in Ethiopia should incorporate screening all
HIV infectedpersons forHBVandHCVmarkers, immunizingpatient
screened negative for HBV markers, and providing health educa-
tion on prevention of HBV and HCV for patients co-infected with
HIV. The current national ART supply chain package in the coun-http://dx.doi.org/10.1016/j.ijid.2012.05.223
